Key highlights
- Revenue for the third quarter of 2026 grew to $4 million from $2.2 million in the prior-year period
- Management raised full-year 2026 revenue guidance to a range of $35 million to $39 million
- Contracted potential milestone payments across active partner programs now exceed $3 billion
- Year-to-date revenue reached $31.8 million through September 30, 2026
- Cash and cash equivalents guidance for year-end 2026 was increased to a range of $53 million to $57 million
- A major partnership was established with Eli Lilly to utilize OmniAb antibody discovery technologies
Financial Performance
OmniAb delivered a third-quarter revenue of $4 million, marking an increase from the $2.2 million reported in the third quarter of 2025. This performance contributed to a year-to-date revenue total of $31.8 million. The revenue growth was primarily driven by the achievement of technical and clinical milestones within the company's partner portfolio. Alongside the revenue gains, management updated its liquidity outlook, now projecting year-end cash and cash equivalents to fall between $53 million and $57 million, an increase from previous estimates.
Up 2.9% since our story on 30 Oct: $4.75 when we broke it → $4.89 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $4.69 |
|---|---|
| 20 Oct | $4.96 |
| 21 Oct | $4.92 |
| 22 Oct | $4.78 |
| 23 Oct | $4.66 |
| 26 Oct | $4.61 |
| 27 Oct | $4.96 |
| 28 Oct | $5.28 |
| 29 Oct | $5.23 |
| 30 Oct | $5.11 |
| 2 Nov | $5.09 |
| 3 Nov | $5.15 |
| 4 Nov | $5.18 |
| 5 Nov | $4.83 |
| 6 Nov | $5.03 |
| 9 Nov | $5.30 |
| 10 Nov | $5.10 |
| 11 Nov | $5.10 |
| 12 Nov | $4.95 |
| 13 Nov | $4.91 |
| 16 Nov | $4.89 |
Management Outlook
The company has demonstrated a consistent trend of upward revisions to its 2026 financial targets. Beginning the year with a revenue guidance range of $25 million to $30 million in March, the forecast was incrementally raised to $28 million to $33 million in May, then to $32 million to $36 million in August, and finally to the current range of $35 million to $39 million. Looking further ahead, management expressed expectations for exploration revenue to double in 2027 as the partnership pipeline matures and discovery activities scale.
Business Overview
OmniAb operates as a biotechnology platform provider, offering pharmaceutical partners access to a diverse array of transgenic animals and high-throughput screening technologies for antibody discovery. The business model relies on a combination of upfront license fees, research funding, and downstream milestone and royalty payments. As of late 2026, the company maintains a robust portfolio of active programs with a total contracted potential milestone value exceeding $3 billion.
Sector Dynamics
In the broader biotechnology sector, platform companies are increasingly evaluated on their ability to secure high-value partnerships with major pharmaceutical entities. The recent collaboration between OmniAb and Eli Lilly serves as a focal point for the company's current discovery efforts. Analysts on the call focused on the nuances of royalty structures, particularly regarding Baticlimab, and the sustainability of pull-through rates for exploration consumables in the current clinical research environment.
What to Watch
- Primary completion results for up to 19 partner-led clinical trials scheduled through late 2026 and 2027
- Updates on the pull-through rates for exploration consumables and their impact on 2027 revenue growth
- Management presentations at several upcoming investor conferences scheduled for November 2026
- Clarity on royalty pricing and commercialization milestones for the Baticlimab program
- The impact of the Eli Lilly partnership on the company's short-term milestone realization
| Date | Announcement | Amount |
|---|---|---|
| 06 Aug 2026 | Q2 2026 revenue; raised FY 2026 revenue guidance to $32M–$36MSource: stocktitan.net | $13.4 Million |
| 07 May 2026 | Q1 2026 revenue; raised FY 2026 revenue guidance to $28M–$33MSource: SEC filing | $14.4 Million |
| 04 Mar 2026 | Q4 2025 revenue; introduced FY 2026 revenue guidance of $25M–$30MSource: investors.omniab.com | $8.4 Million |
| 04 Nov 2025 | Q3 2025 revenue; lowered FY 2025 revenue guidance to $18M–$22MSource: investors.omniab.com | $2.2 Million |
| 06 Aug 2025 | Q2 2025 revenue; affirmed FY 2025 revenue guidance of $20M–$25MSource: investors.omniab.com | $3.9 Million |
| Share price | $4.75 |
|---|---|
| Market cap | $691M |
| Revenue (annual) | $19M |
| 1-month price change | -4.23% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by OmniAb, Inc. announcing third quarter 2026 financial results and updated 2026 guidance.
Track OmniAb, Inc. live
Get the next OmniAb, Inc. SEC filing seconds after it lands.



